ReviewBiomedical optics express2026
AI-driven digital holographic microscopy for label-free quantitative cellular analysis: toward low-cost and field-deployable platforms.
Review in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal Optical Biosensing for Precision Medicine and Healthcare: Introduction to the feature issue.Biomedical optics express · 2026Article
- Advances in Digital Holography, 3-D Imaging, and Optical Information Processing: introduction.Biomedical optics express · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in artificial intelligence (AI) and digital holographic microscopy (DHM) has enabled quantitative, label-free, and noninvasive cellular imaging with unprecedented precision. This review provides an overview of AI-driven DHM technologies that transform classical holographic phase reconstruction and cellular analysis into real-time, portable biomedical solutions. After outlining the optical and computational fundamentals of DHM and quantitative phase imaging, we describe how deep generative and diffusion models substantially enhance phase retrieval accuracy under noisy or single-shot conditions. We then summarize recent biomedical applications, integrating blood, cancer, and cardiac cell analyses into a unified framework of AI-assisted quantitative phenotyping. Deep and self-supervised learning approaches are shown to enable high-accuracy classification of red blood cells and cancer cells and label-free evaluation of cardiomyocyte contractility and drug response. The combination of AI-based reconstruction, self-supervised learning, and physics-informed modeling demonstrates robust performance even with limited labeled data. Finally, we discuss the system-level transition toward low-cost, edge-AI-enabled DHM platforms capable of real-time phase imaging in point-of-care or field environments. We highlight key challenges in data standardization, interpretability, and multimodal integration. Collectively, this review envisions AI-integrated DHM as a scalable, accessible technology bridging advanced quantitative imaging with practical biomedical diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.